Skip to main content
Back To Top Top Back To Top
This website publishes administrative rules on their effective dates, as designated by the adopting state agencies, colleges, and universities.

Rule 3701:1-58-32 | Use of unsealed radioactive material for uptake, dilution, and excretion studies for which a written directive is not required.

 

Except for quantities that require a written directive under paragraph (B) of rule 3701:1-58-15 of the Administrative Code, a licensee may use any unsealed radioactive material prepared for medical use for uptake, dilution, or excretion studies that is:

(A) Obtained from:

(1) A manufacturer or preparer licensed under rule 3701:1-46-43 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirements; or

(2) A PET radioactive drug producer licensed in accordance with paragraph (I) of rule 3701:1-40-14 of the Administrative Code or equivalent United States nuclear regulatory commission or agreement state requirement; or

(B) Excluding production of PET radionuclides, prepared by:

(1) An authorized nuclear pharmacist; or

(2) A physician who is an authorized user and who meets the requirements specified in rule 3701:1-58-36, or rule 3701:1-58-40 and paragraph (C)(1)(b)(vii) of rule 3701:1-58-36 of the Administrative Code; or

(3) An individual under the supervision, as specified in rule 3701:1-58-14 of the Administrative Code, of the authorized nuclear pharmacist in paragraph (B)(1) of this rule or the physician who is an authorized user in paragraph (B)(2) of this rule; or

(C) Obtained from and prepared by an United States nuclear regulatory commission or agreement state licensee for use in research in accordance with a radioactive drug research committee-approved protocol or an investigational new drug protocol accepted by United States food and drug administration; or

(D) Prepared by the licensee for use in research in accordance with a radioactive drug research committee-approved application or an investigational new drug protocol accepted by United States food and drug administration.

Last updated November 18, 2022 at 8:33 AM

Supplemental Information

Authorized By: 3748.02, 3748.04
Amplifies: 3748.04
Five Year Review Date: 4/7/2027
Prior Effective Dates: 8/15/2005, 12/22/2008